Brad Schenkel, MSc: Predicting Hospitalizations, ER Visits Among CLL Patients

• Date :
• 4    
  0

HIV-Associated Lymphoma: Treatment Patterns and Survival in the Antiretroviral Era

• Date :
• 4    
  0

The PROs of Patient-Reported Outcomes

• Date :
• 3    
  0

CLL-IPI: A New and Improved Staging System for CLL?

• Date :
• 3    
  0

Evolving Issues in Anticoagulation

• Date :
• 3    
  0

Eligibility Criteria Not Associated with Adverse Events in RCTs

• Date :
• 3    
  0

Get Involved with Health Volunteers Overseas

• Date :
• 2    
  0

Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

• Date :
• 2    
  0

Collaborative Care Delivery Reduces Travel Burden for AML Patients

• Date :
• 2    
  0

American Society of Hematology American Society of Hematology S'abonner2 816 Ajouter à Partager Plus 102 vues 1 0 Ajoutée le 18 juin 2015 Jeremy Slade Abramson, MD, on findings from a phase II trial comparing brentuximab vedotin with or without AVD

• Date :
• 2    
  0

Controversy over Quality - Does pay-for-performance work?

• Date :
• 2    
  0

New Biomarkers and Prognostic Indicators in Leukemia and MDS

• Date :
• 1    
  0

Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with Acute Lymphoblastic Leukemia (ALL)

• Date :
• 1    
  0

The Future of Clinical and Translational Research in Hematologic Malignancies

• Date :
• 1    
  0

Ruxolitinib in CMML: Study Shows Promising Results

• Date :
• 1    
  0

Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL

• Date :
• 1    
  0

Promising Cardiac and Renal Responses with NEOD001 in Patients with AL Amyloidosis

• Date :
• 1    
  0

Optimizing Therapy in Sickle Cell Disease

• Date :
• 1    
  0

Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL

• Date :
• 1    
  0

Newly Approved Drugs: How Should Do We Use Them in the Clinic?

• Date :
• 1    
  0

New Approaches in CLL and Prolymphocytic Leukemia

• Date :
• 1    
  0

Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma

• Date :
• 1    
  0

Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?

• Date :
• 1    
  0

Induction Chemotherapy for AML: Understanding the Patient Experience

• Date :
• 1    
  0

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia

• Date :
• 1    
  0

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients

• Date :
• 1    
  0

Improving Quality of VTE Care

• Date :
• 0    
  0

Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

• Date :
• 0    
  0

Options for Treating the High-Risk APL Patient

• Date :
• 0    
  0

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

• Date :
• 0    
  0

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

• Date :
• 0    
  0

Predicting Prognosis in Myelodysplastic Syndromes

• Date :
• 0    
  0

Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL

• Date :
• 0    
  0

How to Get Published in a Peer-Reviewed Journal: Q & A

• Date :
• 0    
  0

How to Get Published in a Peer-Reviewed Journal: Presentation

• Date :
• 0    
  0

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

• Date :
• 0    
  0

The Balancing Act of Caring for Older Patients with Hemophilia

• Date :
• 0    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date :
• 3380    
  6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

• Date :
• 4963    
  0

The European Hematology Association - EHA 2023

• Date :
• 8092    
  0

MDS - 17th International Congress on Myelodysplastic Syndromes

• Date :
• 12637    
  0

43e congrès annuel de la Société Française d’Hématologie - SFH 2023

• Date :
• 9346    
  7